MycoTechnology's Adorvia Brings Fungi-Derived Sweet Proteins to the Sugar Reduction Race
- Gauri Khanna
- 22 hours ago
- 3 min read
Colorado-based MycoTechnology has launched Adorvia, a range of fungi-derived sweet proteins designed to reduce sugar and stevia in food and beverage products.
The proteins are produced through a proprietary fermentation process that uses fungal biology to express sweet proteins, offering a natural alternative to conventional high-intensity sweeteners.
If the technology scales commercially, it could give food manufacturers a new tool in the long-running effort to cut added sugar without sacrificing taste.
A New Entrant in the Sweetener Market
Sugar reduction has been one of the food industry's most persistent challenges. Consumers want less sugar; they also want products that taste as though nothing has changed. High-intensity sweeteners such as stevia and monk fruit have filled part of that gap, but both carry flavour liabilities: stevia in particular is associated with a bitter, lingering aftertaste that limits its use at higher concentrations.
MycoTechnology, a Colorado-based food technology company, is positioning its new Adorvia platform as a solution to precisely that problem. The company has launched a range of fungi-derived sweet proteins intended to work alongside, and reduce the quantity of, both sugar and existing sweeteners such as stevia. The proteins are produced using MycoTechnology's proprietary fermentation process, which applies fungal biology to express sweet proteins at commercial scale.
The broader Adorvia range includes two product lines: Adorvia SB, which targets sugar and bitterness reduction, and Zukora, a sweet protein designed to function as a direct sweetener in its own right.
How Fungal Fermentation Produces Sweetness
Sweet proteins are a naturally occurring class of compounds, found in certain tropical fruits, that bind to human taste receptors and produce a sweet sensation at concentrations far lower than sucrose. The scientific interest in sweet proteins is not new, but producing them at viable commercial scale has historically been difficult using conventional extraction or synthesis methods.
MycoTechnology's approach applies fungal fermentation to address that production challenge. The company uses its established fermentation platform, previously deployed across bitter-reduction and flavour-modulation ingredients, to express these proteins biologically. The result, according to the company, is a clean-label ingredient that can be positioned as natural and that does not carry the regulatory complexity associated with some synthetic sweeteners.
Adorvia SB is described as functioning primarily as a taste modulator: reducing the perception of bitterness from stevia while simultaneously allowing manufacturers to lower overall sugar content. Zukora, the dedicated sweet protein ingredient, is aimed at applications where a more direct sweetening effect is needed. The company indicates the ingredients are suitable across beverage, dairy, confectionery, and snack applications, though specific formulation data has not been publicly disclosed.
This approach to fungal fermentation for food ingredients is part of a broader wave of companies applying microbial and fungal biology to taste and texture challenges that conventional agriculture and chemistry have struggled to solve cleanly.
Commercial Context and What Comes Next
MycoTechnology is not a newcomer to the ingredients market. The company built its early reputation on PureTaste, a bitter-blocking technology that uses mycelium fermentation to reduce off-notes in plant-based proteins and beverages. Adorvia represents an extension of that platform into the sweetener category, which is a considerably larger and more competitive market.
The sugar reduction ingredient sector includes well-resourced incumbents: Ingredion, Givaudan, and IFF all have active programmes in taste modulation and sweetener systems. For Adorvia to gain meaningful commercial traction, MycoTechnology will need to demonstrate performance advantages in real formulations, at competitive cost, and with a regulatory pathway that satisfies markets beyond the United States.
On that last point, the source material does not detail the regulatory status of Adorvia or Zukora in the EU, UK, or Asia-Pacific markets, which is a material gap for any ingredient company with global ambitions.
The broader fermentation-derived ingredients sector has attracted sustained investor interest, but commercial scale-up remains the defining test. MycoTechnology has not disclosed production capacity, pricing, or customer pipeline for the Adorvia range.
What the launch does confirm is that fungal fermentation platforms are reaching into categories beyond protein and packaging. Whether sweet proteins produced this way can genuinely displace stevia at scale, and at a cost food manufacturers will accept, remains an open question. The taste science is plausible; the commercial proof will take time.
